Characteristics of Pain in Women With Lipoedema

November 8, 2021 updated by: Glasgow Caledonian University

Pain Characteristics, Intensity, Patterns, Impact and Quality of Life in Women With Lipoedema: an Online Survey

This observational study will seek to investigate the following questions in women with lipoedema:

  • pain characteristics, intensity and patterns of pain
  • the relationships between the characteristics, intensity and patterns of pain and age, ethnicity, location, employment status, levels of anxiety/depression, walking ability, ability to work, relations with other people, impact on sleep and quality of life.
  • the impact of pain treatments or medications on the intensity of pain. The information will be collected via an online survey and participants will be recruited through social media platforms.

Study Overview

Status

Recruiting

Conditions

Detailed Description

Lipoedema is a chronic adipose tissue disorder that occurs almost exclusively in women and affects approximately 11% worldwide. Pain is a recurring feature described by people with lipoedema (pwL) with a recent study reporting 88.3% of patients indicating pain as a clinical feature. It has been suggested, with chronic long-term conditions, that the pain people experience can be moulded by a myriad of elements.This includes biomedical, psychosocial (e.g. patients' beliefs, expectations, and mood), and behavioural factors (e.g. context, responses by significant others). PwL often experience significant impairment in their daily activities and quality of life. It has further been found that psychological and the biomedical consequences of lipoedema can increase the chances of anxiety and depression which can subsequently further impact on quality of life and pain experience.

This observational study will seek to investigate the following questions in women with lipoedema:

  • pain characteristics, intensity and patterns of pain
  • the relationships between the characteristics, intensity and patterns of pain and age, ethnicity, location, employment status, levels of anxiety/depression, walking ability, ability to work, relations with other people, impact on sleep and quality of life.
  • the impact of pain treatments or medications on the intensity of pain. INformation about pain characteristics, demographics, mood, functional ability and quality of life will be collected via an online survey and participants will be recruited through social media platforms.

Study Type

Observational

Enrollment (Anticipated)

200

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

16 years and older (Child, Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Sampling Method

Non-Probability Sample

Study Population

Women with lipoedema.

Description

Inclusion Criteria:

  • Women with lipoedema
  • 16 years and older

Exclusion Criteria:

- Inability to provide consent

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Only
  • Time Perspectives: Cross-Sectional

Cohorts and Interventions

Group / Cohort
Women with Lipoedema
No interventions administered.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Brief Pain Inventory - short form
Time Frame: Only once at participation, the study duration is approximately 2 years
The Brief Pain Inventory - Short Form is a simple, 9 question self-reporting tool that expands on other questionnaires such as the McGill pain questionnaire which focuses more on the quality of pain. The questionnaire allows the individual to rate the severity of pain and it also looks at how pain affects daily functions and discloses the site of pain in the past 24 hours. Within the questionnaire there are four severity questions looking at pain 'at least', 'at worst' (both in the last 24 hours), 'on average' and 'now' using a Likert scale with 0 = no pain to 10 = pain as bad as you can imagine. Seven pain interference domains are also included in the questionnaire covering general activity, mood, walking ability, normal work, relations with others, sleep and enjoyment of life. These are also measured on a Likert scale with 0 = no interference to 10 = interferes completely.
Only once at participation, the study duration is approximately 2 years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Symptoms severity scale
Time Frame: During study, only once at participation - 2 years

Symptom severity will be recorded using a 5 - point Likert scale with 1 = no problem to 5 = extremely severe. These symptoms include:

  1. swelling of the affected areas,
  2. loose connective tissues around the knee joints,
  3. tenderness,
  4. easy or spontaneous bruising, and
  5. presence of spider veins.
During study, only once at participation - 2 years
Depression, Anxiety and Stress Scale - 21
Time Frame: Only once at participation, the study duration is approximately 2 years
The Depression, Anxiety and Stress Scale - 21 is a a self-reporting questionnaire with three scales measuring three negative emotional states: depression, anxiety, and stress. Within the questionnaire, each of the three scales contain 7 items with the scores of these items totalled. Each item is score on a likert scale of 0 to 3: 0 being ' did not apply to me at all', 1 being 'applied to me to some degree, or some of the time, 2 being 'applied to me to a considerable degree' or a good part of the time', 3 being 'applied to me very much or most of the time'.
Only once at participation, the study duration is approximately 2 years
World Health Organization Quality of Life Assessment
Time Frame: Only once at participation, the study duration is approximately 2 years
The World Health Organization Quality of Life Assessment is a shorter version of the initially developed questionnaire with 100 items, with this shorter version containing 26 items. It measures the broad domains of physical health, psychological health, social relationships, and environment. For each of these domains a mean score is produced for use within research and analysis. The items are rated on a 5-point Likert scale (low score of 1to high score of 5) to determine the raw item score. The the mean for each domain is calculated. After which, the domain score is multiplied by 45 to transform the domain score into a scaled score. A high score indicates a higher quality of life.
Only once at participation, the study duration is approximately 2 years

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Demographic questionnaire
Time Frame: Only once at participation, the study duration is approximately 2 years

Data for the following variables will be collected from the participants:

  • age
  • ethnicity
  • country of domicile
  • employment status
  • height
  • weight
  • number of comorbidities
  • walking aid usage
  • time of awareness of lipoedema
  • type of lipoedema
Only once at participation, the study duration is approximately 2 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Chee Wee Tan, PhD, Glasgow Caledonian University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 1, 2020

Primary Completion (Anticipated)

April 30, 2022

Study Completion (Anticipated)

April 30, 2022

Study Registration Dates

First Submitted

June 2, 2021

First Submitted That Met QC Criteria

November 8, 2021

First Posted (Actual)

November 9, 2021

Study Record Updates

Last Update Posted (Actual)

November 9, 2021

Last Update Submitted That Met QC Criteria

November 8, 2021

Last Verified

November 1, 2021

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • EC2_CWT

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Lipedema

3
Subscribe